Safeguarding Molecular Tuberculosis Diagnosis in Viet Nam: Specimen Selection, Result Interpretation and Drug-Resistance Testing Pathways

DIAGNOSTIC SAFETY & RISK MANAGEMENTMEASUREMENT, LEARNING & IMPROVEMENT

11/5/202625 min read

Safeguarding Molecular Tuberculosis Diagnosis in Viet Nam: Specimen Selection, Result Interpretation and Drug-Resistance Testing Pathways

A patient with a persistent cough, weight loss, and an abnormal chest radiograph undergoes a rapid molecular test for tuberculosis. The result is negative. Does this mean tuberculosis can be excluded?

Another patient receives a positive molecular result, but the assay provides no information about resistance to rifampicin. Tuberculosis has been detected, yet an important question remains unanswered: what additional investigation is needed to obtain the drug-resistance information relevant to clinical management?

These situations illustrate an important challenge as molecular tuberculosis testing becomes more accessible. Rapid diagnostic technologies can improve bacteriological detection and support earlier clinical decisions, but the reliability of the diagnostic process depends on more than the analytical performance of an individual test.

The specimen must be appropriate for the suspected disease and the assay being used. Results must be interpreted in light of the patient's clinical circumstances and the method's limitations. When tuberculosis is detected, the healthcare service must also determine whether additional drug-susceptibility testing is indicated and how that information will be obtained.

These responsibilities become particularly important when molecular technologies are introduced into peripheral healthcare facilities or other settings outside conventional laboratory environments.

On November 3, 2026, the World Health Organization (WHO) published the second edition of its consolidated guidelines on tuberculosis diagnosis. The updated publication brings together recommendations for detecting tuberculosis infection, disease, and drug resistance, including new approaches involving near point-of-care molecular testing, tongue swabs, and sputum pooling under exceptional resource constraints.

These developments offer opportunities to improve diagnostic access, particularly for patients who may otherwise have difficulty obtaining appropriate laboratory investigations. They also raise practical questions about specimen selection, quality assurance, result interpretation, and the availability of subsequent drug-resistance testing.

For healthcare organizations in Viet Nam, progress should not be measured simply by the number of molecular tests performed or how quickly an initial result becomes available. The more meaningful question is whether testing produces reliable information, whether its limitations are understood, and whether the diagnostic pathway can provide the additional information needed for appropriate patient care.

Molecular Detection Does Not Necessarily Complete the Diagnostic Assessment

Molecular tests for tuberculosis commonly use nucleic acid amplification technologies to detect genetic material associated with the Mycobacterium tuberculosis complex.

Compared with conventional smear microscopy, WHO-recommended molecular rapid diagnostic tests can offer important improvements in detecting tuberculosis, including in specimens containing relatively few organisms. Some assays can also identify genetic changes associated with resistance to particular anti-tuberculosis medicines.

However, molecular technologies differ considerably in what they can detect and report.

An assay designed only to detect the M. tuberculosis complex cannot determine drug susceptibility. Another assay may detect tuberculosis and rifampicin resistance but provide no information about resistance to isoniazid, fluoroquinolones, or other medicines relevant to clinical management.

More comprehensive molecular methods can examine additional resistance-associated genetic regions, but their usefulness depends on the mutations covered, analytical performance, specimen characteristics, and interpretation of the findings.

The distinction between detecting tuberculosis and assessing drug resistance is fundamental.

A positive molecular result indicates that the targeted genetic material was detected under the assay's validated conditions. It does not necessarily establish bacterial viability, determine the complete resistance profile, or resolve every question relevant to the patient's clinical condition.

Molecular assays may detect residual genetic material from nonviable organisms, particularly in some patients who have previously received tuberculosis treatment. This can complicate interpretation when the clinical question concerns possible recurrent or persistent disease.

Conversely, a negative result does not always exclude active tuberculosis. Detection may be limited by a low bacterial burden, an unsuitable specimen, or differences between the suspected site of disease and the material examined.

These limitations do not diminish the value of molecular testing. They explain why the result must be considered alongside the patient's clinical presentation, other investigations, and the circumstances in which the specimen was obtained.

A reliable diagnostic service should be able to identify what each assay establishes, what remains uncertain, and which additional investigations may be appropriate.

Specimen Selection Must Reflect the Suspected Disease

One of the most important decisions occurs before molecular analysis begins: which specimen is most appropriate for the patient and the suspected form of tuberculosis?

For adults and adolescents with suspected pulmonary tuberculosis, sputum remains a preferred specimen when it can be obtained and is appropriate for the selected molecular assay.

However, not every patient can produce sputum. Some have a dry cough, while others experience physical limitations or clinical conditions that make expectoration difficult. Patients with low bacterial burdens may also present diagnostic challenges even when respiratory specimens are available.

Repeatedly requesting a specimen that a patient cannot provide may delay meaningful investigation. Alternative collection methods can improve access, but their suitability depends on the patient population, suspected disease site, molecular platform, and available evidence.

The distinction becomes particularly important in extrapulmonary tuberculosis.

Suspected tuberculosis involving the central nervous system, lymph nodes, pleura, or other anatomical sites may require cerebrospinal fluid, aspirates, tissue, or other clinically appropriate specimens.

Not every molecular assay has been evaluated or authorized for every specimen type. A test that performs well on sputum should not automatically be assumed to provide equivalent sensitivity or specificity when applied to another biological material.

The consequences of inappropriate specimen selection can be significant. A negative molecular result obtained from material that does not adequately represent the suspected site of disease may offer limited reassurance, even when the analytical procedure was performed correctly.

Healthcare organizations should therefore establish which specimen types are appropriate for their available assays and how clinicians can obtain laboratory or specialist advice when the preferred specimen cannot be collected.

The objective is not to collect as many specimens as possible. It is to obtain the most informative material available for the clinical question while minimizing unnecessary procedures and recognizing the limitations of the chosen approach.

What the WHO 2026 Guidelines Change

The second edition of the WHO consolidated tuberculosis diagnostic guidelines, published on November 3, 2026, introduces several developments with practical implications for diagnostic service design.

One of the most important is the recommendation of near point-of-care nucleic acid amplification tests, known as NPOC-NAATs, as a new diagnostic technology class.

These tests are designed to bring molecular tuberculosis detection closer to patients, including in peripheral laboratories, primary healthcare facilities, mobile services, and selected community settings.

They can operate with less infrastructure than conventional molecular laboratory systems, potentially improving access in locations where rapid molecular testing has previously been unavailable.

For adults and adolescents with signs or symptoms of pulmonary tuberculosis, or who screen positive for pulmonary tuberculosis, WHO recommends NPOC-NAATs on sputum as initial diagnostic tests rather than smear microscopy. This is a strong recommendation supported by moderate-certainty evidence.

When sputum cannot be obtained, WHO also recommends NPOC-NAATs on tongue swabs for this population. The recommendation is likewise strong, with moderate certainty of evidence.

An important qualification is that sputum remains the preferred specimen whenever it can be collected because it generally provides better diagnostic accuracy than tongue swabs.

NPOC-NAATs are intended to complement existing molecular diagnostic networks, particularly where access is limited. WHO does not recommend replacing established low-complexity or moderate-complexity molecular testing systems indiscriminately with the new class.

The new class generally has lower diagnostic sensitivity than some existing molecular platforms and currently does not provide information about rifampicin resistance.

Consequently, positive NPOC-NAAT findings must be connected to an appropriate pathway for subsequent drug-susceptibility testing. WHO emphasizes that remaining or newly collected specimens from positive tests should be referred for this purpose.

This arrangement should be established before a decentralized testing service begins operating, rather than after patients start receiving positive results.

WHO has also updated its recommendations for tongue swabs used with low-complexity automated nucleic acid amplification tests, known as LC-aNAATs.

For adults and adolescents with suspected pulmonary tuberculosis who cannot provide respiratory specimens, appropriately selected LC-aNAATs on tongue swabs may be used as initial diagnostic tests.

Unlike the NPOC-NAAT tongue-swab recommendation, this is a conditional recommendation supported by low-certainty evidence.

The distinction matters. Both approaches may improve access to bacteriological testing, but their evidence bases, recommendation strengths, and analytical capabilities are not identical.

Depending on the specific assay, an LC-aNAAT system may provide information about tuberculosis detection and rifampicin resistance, whereas the currently recommended NPOC-NAAT class does not provide that resistance result.

Healthcare organizations must therefore understand the capabilities and limitations of the product they intend to use rather than assume that all molecular technologies offer equivalent diagnostic information.

WHO has also established an evolving list of recommended tuberculosis diagnostic classes and products, including information about WHO prequalification status.

Recommendation of a diagnostic class, inclusion of a particular product in WHO's listing, and completion of WHO prequalification are related but distinct matters.

The relevant product information may change as additional technologies undergo assessment and prequalification. A recommendation for one product should not automatically be extended to another product merely because the two appear to belong to the same technology class.

The updated WHO consolidated guidelines are now available, while the supporting operational handbook for the second edition remains under development. The WHO operational handbook published in 2025 continues to provide relevant implementation guidance where applicable, but it should not be treated as a completed operational manual for every newly recommended approach.

Tongue Swabs Can Improve Access, but Their Limitations Matter

Tongue swabs may provide a practical collection option for patients who cannot produce sputum. They are generally easier to collect than some respiratory specimens and may support decentralized testing when used with an appropriate molecular platform.

Their potential value is particularly relevant when they allow patients who would otherwise lack access to suitable molecular testing to receive an initial bacteriological assessment.

However, changing the specimen type can affect diagnostic performance.

A tongue swab does not sample the respiratory tract in the same way as sputum. The quantity of detectable tuberculosis genetic material may be lower, and a negative result may therefore provide less reassurance than a negative result obtained from a suitable respiratory specimen.

The WHO recommendations also distinguish different patient populations.

The new tongue-swab recommendations principally address adults and adolescents. WHO does not currently recommend tongue swabs as part of routine molecular diagnostic strategies for children because the available evidence is insufficient or indicates inadequate sensitivity for the approaches evaluated.

This should be distinguished from the use of NPOC-NAATs on sputum in children. WHO has extrapolated that recommendation from adult evidence and limited pediatric data, while acknowledging uncertainty concerning performance in children.

For children with suspected pulmonary tuberculosis, appropriately selected combinations of respiratory and non-respiratory specimens remain important. WHO supports concurrent molecular testing strategies where indicated, including the use of respiratory specimens and stool with appropriate technologies.

People living with HIV require additional consideration.

Where available, concurrent testing with an appropriate LC-aNAAT on a respiratory specimen and urine-based lateral flow lipoarabinomannan testing, known as LF-LAM, remains a preferred WHO-recommended approach for eligible patients.

LF-LAM detects a mycobacterial antigen rather than nucleic acid. It should not be confused with molecular amplification tests.

Where an LC-aNAAT is unavailable, NPOC-NAATs may contribute to an adapted concurrent testing strategy with LF-LAM under the relevant WHO recommendations.

When respiratory specimens cannot be obtained, tongue-swab testing may also have a role in selected adults and adolescents living with HIV.

However, the evidence for some subgroups remains limited, particularly people with advanced HIV disease or severe illness.

These differences illustrate why specimen selection cannot be separated from the intended assay, patient population, and clinical circumstances. A collection method that improves access for one group may be insufficiently evaluated or unsuitable for another.

Tongue-swab collection also requires appropriate infection prevention and biosafety arrangements.

Although the procedure may be relatively simple, healthcare personnel may need to work in close proximity to patients with suspected infectious pulmonary tuberculosis. The WHO technical guidance emphasizes suitable ventilation and protective measures appropriate to this exposure risk.

Healthcare organizations should establish procedures appropriate to the collection environment, infection risk, personnel competence, available protective equipment, and applicable professional requirements.

A Negative Molecular Result Must Not Create False Reassurance

Molecular testing has substantially strengthened tuberculosis diagnosis, but its sensitivity is not absolute.

A negative result may occur when the bacterial burden is below the assay's detection limit, when the selected specimen does not adequately represent the suspected disease site, or when other biological or technical factors affect detection.

This is particularly relevant in paucibacillary tuberculosis, including some presentations in children, people living with HIV, and patients with extrapulmonary disease.

The diagnostic significance of a negative result also depends on the probability of tuberculosis before testing.

A negative finding in a patient with limited clinical suspicion may have a different meaning from the same result in someone with strongly suggestive symptoms, imaging abnormalities, epidemiological risks, or evidence of disease at an extrapulmonary site.

Additional investigation may be appropriate when significant clinical suspicion remains.

Depending on the circumstances, this may involve another specimen type, microbiological culture, histopathological examination, imaging, or specialist assessment.

However, not every negative molecular result requires repeated testing. The decision should reflect the original diagnostic question, the limitations of the examination, the patient's condition, and the potential value of further investigations.

An important reporting safeguard is to avoid converting the laboratory statement "not detected" into an unsupported clinical conclusion that tuberculosis has been excluded.

A molecular report should communicate what the assay did or did not detect in the particular specimen examined. It should not imply that the test has resolved diagnostic questions beyond its validated capabilities.

Interpreting Xpert Ultra Trace Results and Undetermined Resistance

Some molecular findings require more careful interpretation than a straightforward positive or negative classification.

Xpert MTB/RIF Ultra may report a very low-level tuberculosis detection category known as "trace."

This indicates detection of tuberculosis-associated genetic material at a level where the assay cannot provide a determinate rifampicin-resistance result.

A trace finding should not automatically be classified as an invalid test. It should also not be interpreted as proof that the detected organism is susceptible to rifampicin.

Its significance depends on the patient's age, HIV status, suspected site of disease, previous tuberculosis treatment, and likelihood of active disease.

In some patients with previous tuberculosis treatment, low-level molecular detection may reflect residual genetic material from nonviable organisms rather than ongoing active infection.

This does not necessarily mean that the instrument produced an analytical false-positive result. Genetic material may genuinely be present even when it does not establish that viable organisms are causing active disease.

Conversely, a trace result may be diagnostically important in a patient with substantial clinical suspicion and limited available bacteriological evidence.

Viet Nam's Ministry of Health issued Decision No. 162/QD-BYT on January 19, 2024, promulgating the professional guideline Guidance on Diagnosis, Treatment and Prevention of Tuberculosis.

The guideline contains specific algorithms for interpreting and managing Xpert Ultra trace results. These distinguish relevant patient groups, including children, people living with HIV, patients with suspected extrapulmonary tuberculosis, and individuals with previous tuberculosis treatment.

The algorithms also consider circumstances in which additional investigations and evaluation of drug resistance may be necessary.

This approach helps prevent one interpretation rule from being applied to every trace finding.

Undetermined rifampicin resistance also requires careful assessment.

A result stating that rifampicin resistance could not be determined is not equivalent to confirmed susceptibility.

Importantly, an indeterminate rifampicin result is not always explained by a very low bacterial burden. Depending on the assay and result pattern, other factors, including particular genetic changes or technical limitations, may require consideration.

The Vietnamese guideline distinguishes Xpert Ultra trace findings from other situations in which tuberculosis is detected but rifampicin resistance remains undetermined.

Additional molecular testing, culture-based drug-susceptibility testing, sequencing, or specialist assessment may be necessary in selected circumstances.

For quality management, the important principle is that unusual or incomplete result categories must be connected to appropriate interpretive and follow-on testing arrangements.

The healthcare organization should provide access to relevant guidance and laboratory support so that clinicians are not left to resolve uncommon result patterns without an established process.

Drug-Resistance Testing Must Be Part of the Diagnostic Pathway

Detecting the M. tuberculosis complex is an important diagnostic step, but it does not necessarily complete the information required for patient management.

The next question may concern resistance to rifampicin or other anti-tuberculosis medicines relevant to treatment selection.

Different molecular technologies address this question differently.

Xpert MTB/RIF and Xpert MTB/RIF Ultra can provide tuberculosis detection and rifampicin-resistance information within the same assay.

Other technologies require separate tests for initial detection and subsequent resistance assessment. For example, Truenat MTB or Truenat MTB Plus testing may be followed by the separate Truenat MTB-RIF Dx assay to assess rifampicin resistance.

The new WHO-recommended NPOC-NAAT class currently detects tuberculosis without determining rifampicin resistance.

Healthcare organizations using these technologies must therefore distinguish between obtaining an initial positive molecular result and completing the indicated drug-resistance assessment.

The appropriate follow-on investigation depends on the initial assay, specimen availability, previous results, patient-specific resistance risks, and testing capabilities within the healthcare network.

Additional methods may include molecular resistance assays, line probe assays, targeted next-generation sequencing, or culture-based phenotypic drug-susceptibility testing.

These methods have different capabilities and limitations.

Molecular resistance tests identify selected genetic changes associated with resistance. Their performance depends on the targets examined, mutations covered, and analytical characteristics of the assay.

Phenotypic drug-susceptibility testing evaluates microbial growth under specified drug exposure conditions. It may require more time and can involve technical challenges that differ between medicines.

Targeted next-generation sequencing can provide broader information about resistance-associated genetic regions for multiple drugs. However, interpretation depends on sequence quality, adequate coverage, validated methods, and current knowledge of resistance-associated mutations.

No single method should be assumed to answer every drug-resistance question.

A report stating that rifampicin resistance was not detected does not demonstrate susceptibility to all other anti-tuberculosis medicines.

Similarly, detection of rifampicin resistance should not automatically be presented as a complete multidrug-resistance profile without considering applicable definitions and additional evidence.

Discordant results between molecular and phenotypic methods require appropriate professional investigation. Differences may involve specific mutations, assay coverage, drug concentrations, specimen characteristics, or other technical limitations.

For healthcare organizations, the important question is whether there is a dependable arrangement for completing the necessary resistance assessment.

A diagnostic program should not be judged successful solely because it can detect tuberculosis rapidly if clinically important resistance information remains unavailable, delayed, or inadequately reviewed.

Decentralized Testing Creates New Quality Responsibilities

Near point-of-care molecular technologies may improve access to tuberculosis testing in peripheral healthcare facilities, primary care services, mobile units, and selected community settings.

This can be particularly valuable where patients would otherwise need to travel long distances or wait for specimens to be transported to central laboratories.

However, moving testing closer to the patient also changes the operational environment.

A device designed for relatively simple operation still requires appropriate personnel training, specimen identification, quality assurance, equipment maintenance, result documentation, and procedures for managing unsuccessful or unexpected results.

Staff must understand the specimen types supported by the particular assay and the information it can provide. They also need to know when an instrument-generated result cannot be accepted, when additional testing may be required, and how specimens or diagnostic information should be transferred to another facility.

Infection prevention and biosafety remain essential.

Specimen collection from patients with suspected pulmonary tuberculosis may involve exposure risks. Molecular testing processes may also be vulnerable to cross-contamination or other technical problems when appropriate procedures are not followed.

The required controls depend on the collection method, diagnostic platform, testing environment, and applicable professional requirements.

Decentralization may also create challenges in maintaining a complete diagnostic record.

A patient may receive an initial positive molecular result at a peripheral healthcare facility, while subsequent drug-resistance testing is performed by a referral laboratory.

If the specimen is not referred, the result is not returned, or responsibility for follow-up is unclear, the healthcare system may fail to obtain information necessary for subsequent clinical decisions.

Introducing a faster test can therefore create new vulnerabilities when downstream processes have not been prepared.

Before implementation, healthcare organizations should consider specimen referral capacity, availability of consumables, staff competence, technical support, information systems, and contingency arrangements for equipment or supply interruptions.

The service should establish who is responsible for confirming that indicated follow-on testing has been completed and that relevant findings have reached the clinical team.

Practical implementation resources are available. In May 2026, WHO and the Stop TB Partnership published a near point-of-care and swab-based testing toolkit that includes readiness assessment materials, competency assessment tools, specimen collection procedures, method verification resources, and monitoring templates.

These tools can support local planning, but they should be adapted to the applicable national diagnostic pathways, specific testing systems, and operational circumstances.

Professional responsibility does not disappear when a molecular assay is designed for use outside a conventional laboratory. It must instead be assigned clearly across the personnel and organizations involved.

Sputum Pooling Is a Resource-Constrained Strategy

The WHO 2026 update also introduces a recommendation concerning sputum pooling.

Pooling involves combining portions of sputum specimens from several individuals into one molecular test, with additional individual testing when the pooled result is positive.

The strategy may reduce reagent use, testing costs, and laboratory workload in circumstances where available resources are insufficient for individual testing.

However, pooling introduces a potential tradeoff between efficiency and diagnostic sensitivity.

Combining specimens can dilute genetic material from an individual with a low bacterial burden, increasing the possibility that tuberculosis will not be detected in the pooled examination.

WHO's recommendation is conditional and supported by high-certainty evidence for the evaluated strategy.

It applies to selected adults and adolescents with signs, symptoms, or screening findings suggestive of pulmonary tuberculosis when resource constraints do not allow individual testing.

The recommendation concerns pools containing sputum from up to four individuals, tested with an appropriate low-complexity automated nucleic acid amplification system.

The direct evidence evaluated for this recommendation involved Xpert MTB/RIF Ultra. The findings should not automatically be generalized to all molecular platforms, and WHO has not established an equivalent pooling recommendation for the new NPOC-NAAT class.

The recommendation does not apply to people living with HIV, children, or individuals at increased risk of drug-resistant tuberculosis.

These groups should be prioritized for individual testing because the consequences of reduced sensitivity or delayed diagnosis may be greater.

Pooling requires reliable specimen identification and traceability.

If a pooled sample produces a positive result, the contributing individual specimens must be tested separately to identify which patient or patients have positive findings.

Where rifampicin resistance is detected in a pooled sample, appropriate individual testing is also necessary to establish which patient's specimen contains the resistance-associated finding.

If a pooled result is negative, the testing strategy generally treats the contributing specimens as negative within the pooling algorithm. However, the possibility of reduced sensitivity remains relevant, especially when clinical suspicion is substantial.

The suitability of pooling also depends on the prevalence of positive examinations, specimen quality, testing demand, and the resources needed to resolve positive pools.

The potential efficiency benefit may diminish in settings where a high proportion of pooled samples requires individual retesting.

Available studies also indicate variation in diagnostic accuracy between different collection settings, with some community-based collection approaches showing lower sensitivity than facility-based approaches.

These findings reinforce the importance of evaluating the actual conditions in which pooling would be used.

Pooling should therefore not be presented as a routine quality improvement measure that every laboratory should adopt.

For healthcare organizations in Viet Nam, the existence of a WHO recommendation does not automatically establish that sputum pooling is appropriate or authorized for every testing service.

Any proposed implementation requires assessment of applicable national guidance, intended assay use, regulatory requirements, operational capacity, specimen traceability, and potential consequences for patients.

Measuring Molecular Tuberculosis Diagnostic Reliability

Healthcare organizations commonly monitor molecular testing volume, positivity rates, and laboratory turnaround time.

These figures help describe service activity, but they do not fully establish diagnostic reliability.

An increase in testing volume may reflect expanded access, broader screening, or changes in referral practices. A low positivity rate may reflect a lower-prevalence population rather than inadequate laboratory performance.

Quality measurement should therefore examine whether testing is appropriate for the clinical question and whether the resulting information is sufficiently reliable and complete.

One possible indicator is the proportion of eligible patients receiving an appropriate molecular test according to the applicable national diagnostic pathway.

Another is the proportion of examinations performed using specimen types supported by the selected assay and appropriate for the suspected form of tuberculosis.

For decentralized services, monitoring invalid, error, and no-result outcomes may help identify problems involving specimen handling, operator competence, equipment, or local operating conditions.

These result categories should be distinguished from valid negative findings and valid tuberculosis-positive findings with undetermined drug resistance.

Different outcomes may require different responses.

Another important measure concerns the proportion of patients with positive results from assays that do not assess rifampicin resistance who complete the indicated follow-on testing.

The denominator should reflect the eligible population, with documented exceptions and appropriate consideration of whether testing was completed within a clinically relevant timeframe.

Healthcare organizations may also review the management of Xpert Ultra trace results, unexpected resistance findings, and important discrepancies between molecular and other diagnostic methods.

The purpose should be to establish whether these situations were appropriately assessed, rather than assume that every discrepancy represents an analytical error.

Turnaround time also deserves careful definition.

The interval between specimen collection and the first molecular result differs from the time required to obtain the drug-resistance information necessary for a clinical decision.

A service may report excellent initial turnaround time while patients still experience substantial delays in completing the indicated resistance assessment.

For this reason, measuring the interval from the initial diagnostic investigation to the availability of the required clinical information may provide a more meaningful picture of pathway reliability.

Indicators should be evaluated according to patient population, diagnostic technology, testing location, and other relevant characteristics.

Each measure should have a clear definition, numerator, denominator, data source, and method for handling exceptions.

Performance targets should be supported by appropriate evidence and should not encourage unnecessary testing, inappropriate specimen collection, or premature clinical conclusions.

Learning From Unexpected and Discordant Results

Some of the most useful opportunities for diagnostic quality improvement arise when laboratory and clinical findings do not agree.

A patient may have a positive molecular test but a negative culture. Another may have a negative molecular test despite clinical and radiological findings strongly suggestive of tuberculosis.

A rifampicin-resistance result may also conflict with another molecular or phenotypic drug-susceptibility test.

These discrepancies should not automatically be classified as laboratory errors.

Different methods detect different biological targets, have different analytical sensitivities, and may examine specimens obtained at different times.

Previous treatment can also influence the relationship between molecular detection and culture findings.

A molecular assay may detect genetic material when viable organisms are no longer recoverable by culture. Conversely, a low bacterial burden or limitations in mutation coverage may contribute to differences between diagnostic methods.

Structured review should begin by determining whether the findings are genuinely contradictory and whether the available evidence can explain the difference.

Relevant factors may include specimen type, assay characteristics, bacterial burden, previous treatment, clinical circumstances, and known technical limitations.

Additional testing or specialist microbiological assessment may be appropriate in selected cases.

These reviews can also reveal weaknesses in the diagnostic service.

Repeated indeterminate resistance findings may suggest a need for clearer testing algorithms or improved access to referral laboratories.

A high frequency of invalid results at one location may indicate difficulties involving equipment, specimen processing, or operator training.

Delays in follow-on drug-resistance testing may reflect transport problems, insufficient capacity, or unclear responsibilities between facilities.

The purpose of quality review is not simply to count unusual results. It is to understand how the diagnostic system behaves under difficult circumstances and identify practical opportunities to improve reliability.

Applying International Evidence in Viet Nam

Tuberculosis remains a major public health challenge in Viet Nam.

At the launch of the National Tuberculosis Strategic Plan for 2026–2030 in May 2026, WHO noted that Viet Nam remained among the 30 countries with the highest tuberculosis burden worldwide.

WHO reported approximately 119,000 notified tuberculosis cases in 2025, reflecting progress in detection and access to services.

This figure represents reported cases and should not be confused with the estimated total number of people who developed tuberculosis during the year.

The national strategic plan emphasizes earlier detection, stronger tuberculosis services within primary healthcare, wider participation of healthcare providers, and more sustainable national financing.

These priorities make the reliability of molecular diagnostic services particularly important.

Expanding access to testing can improve opportunities for earlier diagnosis, but the benefits depend on whether patients receive appropriate examinations and whether healthcare services can interpret and act on the findings.

Viet Nam's Ministry of Health issued Decision No. 162/QD-BYT on January 19, 2024, promulgating the professional guideline Guidance on Diagnosis, Treatment and Prevention of Tuberculosis.

The guideline applies to medical examination and treatment facilities and replaced Decision No. 1314/QD-BYT dated March 24, 2020.

It addresses molecular tuberculosis testing, interpretation of Xpert Ultra trace findings, and diagnostic approaches to drug resistance.

The national algorithms include technologies such as Xpert MTB/RIF, Xpert Ultra, Truenat, and other molecular methods within specified clinical contexts.

These provisions provide an important national professional reference for evaluating molecular results and determining additional investigations.

The WHO recommendations published in November 2026 should be considered alongside the applicable Vietnamese guidance.

However, publication of a new international recommendation does not automatically mean that every newly recommended assay, specimen type, or testing strategy has been incorporated into national diagnostic pathways.

Healthcare organizations should distinguish international scientific recommendations from applicable Vietnamese professional guidance, technical requirements, and the conditions governing specific diagnostic products.

Medical device regulation is also relevant.

Decree No. 98/2021/ND-CP on medical device management, as amended and reflected in Consolidated Document No. 08/VBHN-BYT dated March 6, 2026, provides an important reference for the management of medical devices in Viet Nam.

Organizations considering new molecular diagnostic systems should assess the relevant product classification, regulatory status, intended use, and applicable requirements for procurement and operation.

A WHO recommendation concerning a diagnostic technology class does not, by itself, establish that every product within that class has been authorized for every intended use in Viet Nam.

Laboratory quality management provides another important foundation.

TCVN ISO 15189:2025, Medical Laboratories: Requirements for Quality and Competence, is identical to ISO 15189:2022 and replaces TCVN ISO 15189:2014.

It provides a framework for laboratory quality management, technical competence, risk-based processes, and reliability of examination results.

However, publication of this national standard does not automatically mean that every healthcare facility or laboratory is legally required to obtain ISO 15189 accreditation.

The applicable obligations depend on the organization's activities, relevant legislation, and any accreditation or contractual commitments.

Circular No. 01/2013/TT-BYT concerning laboratory quality management should also be considered together with its applicable amendments, including Circular No. 25/2026/TT-BYT, whose relevant amendment took effect on August 15, 2026.

More broadly, the Law on Medical Examination and Treatment No. 15/2023/QH15 and its implementing regulations govern relevant aspects of healthcare organizations' professional activities, authorized services, and responsibilities.

Patient information protection is another consideration.

Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.

Molecular tuberculosis results may contain identifiable health information and other personal data. Where testing is distributed across healthcare facilities or connected through digital reporting systems, organizations should assess applicable requirements concerning lawful processing, confidentiality, authorized access, information security, and data transfers.

Consent requirements, applicable exceptions, and other relevant legal conditions should be considered according to the circumstances.

These legal and professional frameworks should support safe implementation. They should not be interpreted as requiring every healthcare organization to adopt identical molecular testing platforms or operational arrangements.

Building a Reliable Molecular Tuberculosis Diagnostic Service

A useful starting point for quality improvement is to examine how patients move through the diagnostic process and where essential information may be lost, delayed, or misinterpreted.

The healthcare organization should establish whether the selected assay is appropriate for the clinical question, whether staff understand the supported specimen types, and whether the laboratory report accurately communicates the findings and limitations.

When tuberculosis is detected, the clinical team should be able to determine whether the relevant drug-resistance information has already been obtained or whether additional testing is indicated.

If another facility must perform the next investigation, responsibility for arranging the referral and confirming receipt of the result should be clear.

The same principle applies when molecular testing is negative despite significant clinical suspicion, when Xpert Ultra reports trace detection, or when resistance information remains undetermined.

These situations should not depend entirely on individual staff members recognizing unusual findings without access to institutional support.

Standardized diagnostic pathways, suitable personnel training, competence assessment, laboratory consultation, and periodic review of selected cases can help make the process more dependable.

New technologies should be introduced with attention to their effect on the complete diagnostic pathway.

A near point-of-care assay may substantially reduce the time required for initial tuberculosis detection. However, the organization should also assess whether specimen referral, drug-resistance testing, result documentation, and subsequent clinical review remain reliable.

Performance monitoring should connect identified concerns with practical improvement activities.

For example, a peripheral healthcare service may achieve rapid initial detection but experience repeated delays in obtaining rifampicin-resistance results from a referral laboratory.

The improvement opportunity may involve specimen transport, communication procedures, testing capacity, or unclear responsibilities rather than the initial molecular assay.

Similarly, a high rate of invalid results may require assessment of specimen handling, equipment maintenance, staff competence, or environmental conditions.

Quality improvement becomes meaningful when the organization identifies the causes of these problems, introduces appropriate changes, and reassesses whether the diagnostic process has become more dependable.

For healthcare services in Viet Nam, this approach allows molecular tuberculosis testing to be strengthened according to actual clinical needs, available resources, and applicable professional requirements.

From Rapid Detection to Diagnostic Excellence

Molecular testing has transformed the ability of healthcare professionals to detect tuberculosis and identify important forms of drug resistance.

The WHO recommendations published in November 2026 offer further opportunities to extend these benefits to patients who may have difficulty accessing conventional laboratory services.

Yet faster or more accessible testing does not automatically guarantee more reliable diagnosis.

A suitable specimen must be selected, and the result must be interpreted within the assay's capabilities and the patient's clinical circumstances. Uncertainty must be recognized when tuberculosis is not detected despite strong suspicion, when only low-level genetic material is identified, or when drug resistance remains undetermined.

The diagnostic pathway must also provide a dependable means of obtaining any additional information required for clinical decisions.

For healthcare organizations in Viet Nam, the opportunity is to connect advances in molecular technology with stronger quality management, professional accountability, and evidence-informed improvement.

Success should not be measured solely by the number of tests performed or the speed of the first result. It should also be assessed according to whether patients receive appropriate investigations, whether findings are interpreted responsibly, and whether indicated drug-resistance assessments are completed and communicated.

A rapid molecular result can be an important step toward diagnosis. A reliable diagnostic pathway ensures that the result is understood, its limitations are recognized, and essential questions are not left unanswered.

Diagnostic excellence in molecular tuberculosis testing depends not simply on detecting tuberculosis quickly, but on selecting appropriate specimens, interpreting results accurately, and ensuring that the diagnostic pathway provides the information needed for safe and informed clinical care.

Selected References and Regulatory Sources

World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis. Second edition. Geneva: World Health Organization; November 3, 2026. ISBN: 978-92-4-012542-1.

World Health Organization. Near Point-of-Care Nucleic Acid Amplification Tests. WHO tuberculosis diagnostic technical recommendations, 2026.

World Health Organization. Tongue Swabs on Low-Complexity Automated Tests. WHO tuberculosis diagnostic technical recommendations, 2026.

World Health Organization. Pooling of Sputa as a Diagnostic Strategy for Diagnosis of TB When Resources Are Constrained. WHO tuberculosis diagnostic technical recommendations, 2026.

World Health Organization. Near Point-of-Care Tests, Tongue Swabs, and Sputum Pooling for TB: Frequently Asked Questions. WHO technical information, 2026.

World Health Organization. TB Diagnostic Classes and Products: List of Current WHO-Recommended Diagnostic Classes and Included Products. Version 1, October 2026.

World Health Organization and Stop TB Partnership. TB Near Point-of-Care and Swab-Based Testing Toolkit. May 6, 2026.

World Health Organization. WHO Operational Handbook on Tuberculosis: Module 3: Diagnosis. Geneva: World Health Organization; August 5, 2025. ISBN: 978-92-4-011099-1.

World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis. Geneva: World Health Organization; April 16, 2025. ISBN: 978-92-4-010798-4.

World Health Organization. Speech at the 2025 TB Annual Review and Launch of Viet Nam's National TB Strategic Plan 2026–2030. WHO Viet Nam; May 7, 2026.

Ministry of Health of Viet Nam. Decision No. 162/QD-BYT, Promulgating Guidance on Diagnosis, Treatment and Prevention of Tuberculosis. January 19, 2024.

International Organization for Standardization. ISO 15189:2022. Medical Laboratories: Requirements for Quality and Competence.

Viet Nam National Standard. TCVN ISO 15189:2025. Medical Laboratories: Requirements for Quality and Competence. Identical to ISO 15189:2022 and replacing TCVN ISO 15189:2014.

National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. Effective January 1, 2024, as subsequently amended.

Government of Viet Nam. Decree No. 96/2023/ND-CP, detailing certain provisions of the Law on Medical Examination and Treatment, as amended where applicable.

Government of Viet Nam. Decree No. 98/2021/ND-CP on Medical Device Management, as amended and reflected in Consolidated Document No. 08/VBHN-BYT dated March 6, 2026.

Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, guiding the implementation of laboratory quality management at medical examination and treatment facilities, as subsequently amended.

Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, amending and supplementing provisions of Circular No. 01/2013/TT-BYT and other Ministry of Health circulars. Issued June 30, 2026. Relevant amendment effective August 15, 2026.

National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.

Government of Viet Nam. Decree No. 356/2025/ND-CP, detailing certain provisions and implementation measures of the Law on Personal Data Protection. Effective January 1, 2026.

Professional Scope and Disclaimer

This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety, and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement, and quality improvement.

The content is intended for general professional education and discussion. It does not constitute individualized medical advice, a clinical or laboratory diagnosis, a tuberculosis diagnostic or treatment protocol, legal advice, an accreditation assessment, certification, or approval of any healthcare organization, professional, diagnostic device, assay, or software system.

The discussion primarily concerns molecular technologies used to support the diagnosis of tuberculosis disease and the detection of associated drug resistance. Testing for tuberculosis infection, specialized pediatric investigations, extrapulmonary tuberculosis, HIV-associated tuberculosis, and complex drug-resistance scenarios may require additional professional guidance and individualized clinical assessment.

The WHO recommendations published in November 2026 should be interpreted according to their stated populations, diagnostic technology classes, specimen types, evidence limitations, and implementation considerations.

References to WHO-recommended technologies do not imply that every commercially available product has identical diagnostic performance, has completed WHO prequalification, or has been authorized for all relevant uses in Viet Nam.

International professional guidance, national standards, and Vietnamese legal obligations serve different purposes. Publication of an international recommendation does not automatically establish a legally binding requirement for every Vietnamese healthcare organization.

The applicability of Vietnamese laws, technical requirements, professional guidelines, and quality standards depends on the organization's authorized scope of practice, actual service arrangements, applicable regulations, and relevant accreditation or contractual commitments.

Patient-specific decisions concerning specimen collection, molecular result interpretation, additional diagnostic investigations, drug-resistance testing, treatment, and clinical follow-up must be undertaken by appropriately qualified and authorized healthcare professionals in accordance with applicable Vietnamese law, relevant professional standards, authorized service capabilities, and the patient's clinical circumstances.

Diagnostic Excellence Vietnam does not provide tuberculosis diagnostic testing, clinical diagnosis, or treatment services through this educational publication.